1. A management of neutropenia using granulocyte colony stimulating factor support for chemotherapy consisted of docetaxel, cisplatin and 5-fluorouracil in patients with oesophageal squamous cell carcinoma. (5th November 2020) Authors: Katada, Chikatoshi; Sugawara, Mitsuhiro; Hara, Hiroki; Fujii, Hirofumi; Nakajima, Takako Eguchi; Ando, Takayuki; Kojima, Takashi; Watanabe, Akinori; Sakamoto, Yasutoshi; Ishikawa, Hideki; Hosokawa, Ayumu; Hamamoto, Yasuo; Muto, Manabu; Tahara, Makoto; Koizumi, Wasaburo Journal: Japanese journal of clinical oncology Issue: Volume 51:Number 2(2021) Page Start: 199 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Phase I/II Study of XELIRI Plus Bevacizumab as Second‐Line Chemotherapy for Japanese Patients With Metastatic Colorectal Cancer (BIX Study). (3rd October 2014) Authors: Hamamoto, Yasuo; Yamaguchi, Tatsuro; Nishina, Tomohiro; Yamazaki, Kentaro; Ura, Takashi; Nakajima, Takako; Goto, Ayumu; Shimada, Ken; Nakayama, Norisuke; Sakamoto, Junichi; Morita, Satoshi; Yamada, Yasuhide Journal: Oncologist Issue: Volume 19:Number 11(2014) Page Start: 1131 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. ISS1-3-2Prognostic index model for overall survival in advanced unresectable pancreatic cancer from GEST study. (30th October 2015) Authors: Hamamoto, Yasuo; Nagase, Michitaka; Egawa, Shinichi; Ueno, Hideki; Ohkawa, Shinichi; Funakoshi, Akihiro; Nakamori, Shoji; Kanai, Masashi; Ohashi, Yasuo; Furuse, Junji Journal: Annals of oncology Issue: Volume 26(2015)Supplement 7 Page Start: vii74 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Long‐term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer. Issue 5 (29th April 2020) Authors: Kato, Ken; Doki, Yuichiro; Ura, Takashi; Hamamoto, Yasuo; Kojima, Takashi; Tsushima, Takahiro; Hironaka, Shuichi; Hara, Hiroki; Kudo, Toshihiro; Iwasa, Satoru; Muro, Kei; Yasui, Hirofumi; Minashi, Keiko; Yamaguchi, Kensei; Ohtsu, Atsushi; Kitagawa, Yuko Journal: Cancer science Issue: Volume 111:Issue 5(2020) Page Start: 1676 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Management of challenging immune-related gastrointestinal adverse events associated with immune checkpoint inhibitors. (6th September 2018) Authors: Hamamoto, Yasuo; Shin, Natalya; Hoshino, Tomohiro; Kanai, Takanori Journal: Future oncology Issue: Volume 14:Number 30(2018) Page Start: 3187 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Management of elderly patients with esophageal squamous cell cancer. (30th April 2022) Authors: Hamamoto, Yasuo; Murakami, Kentaro; Kato, Ken; Kitagawa, Yuko Journal: Japanese journal of clinical oncology Issue: Volume 52:Number 8(2022) Page Start: 808 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Mesenchymal stem cells regulate epithelial–mesenchymal transition and tumor progression of pancreatic cancer cells. Issue 2 (11th January 2013) Authors: Kabashima‐Niibe, Ayano; Higuchi, Hajime; Takaishi, Hiromasa; Masugi, Yohei; Matsuzaki, Yumi; Mabuchi, Yo; Funakoshi, Shinsuke; Adachi, Masayuki; Hamamoto, Yasuo; Kawachi, Shigeyuki; Aiura, Koichi; Kitagawa, Yuko; Sakamoto, Michiie; Hibi, Toshifumi Journal: Cancer science Issue: Volume 104:Issue 2(2013:Feb.) Page Start: 157 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 10111 (2nd December 2017) Authors: Kang, Yoon-Koo; Boku, Narikazu; Satoh, Taroh; Ryu, Min-Hee; Chao, Yee; Kato, Ken; Chung, Hyun Cheol; Chen, Jen-Shi; Muro, Kei; Kang, Won Ki; Yeh, Kun-Huei; Yoshikawa, Takaki; Oh, Sang Cheul; Bai, Li-Yuan; Tamura, Takao; Lee, Keun-Wook; Hamamoto, Yasuo; Kim, Jong Gwang; Chin, Keisho; Oh, Do-Youn Journal: Lancet Issue: Volume 390:Issue 10111(2017) Page Start: 2461 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. Issue 5 (May 2017) Authors: Kudo, Toshihiro; Hamamoto, Yasuo; Kato, Ken; Ura, Takashi; Kojima, Takashi; Tsushima, Takahiro; Hironaka, Shuichi; Hara, Hiroki; Satoh, Taroh; Iwasa, Satoru; Muro, Kei; Yasui, Hirofumi; Minashi, Keiko; Yamaguchi, Kensei; Ohtsu, Atsushi; Doki, Yuichiro; Kitagawa, Yuko Journal: Lancet oncology Issue: Volume 18:Issue 5(2017:May) Page Start: 631 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Issue 11 (November 2019) Authors: Kato, Ken; Cho, Byoung Chul; Takahashi, Masanobu; Okada, Morihito; Lin, Chen-Yuan; Chin, Keisho; Kadowaki, Shigenori; Ahn, Myung-Ju; Hamamoto, Yasuo; Doki, Yuichiro; Yen, Chueh-Chuan; Kubota, Yutaro; Kim, Sung-Bae; Hsu, Chih-Hung; Holtved, Eva; Xynos, Ioannis; Kodani, Mamoru; Kitagawa, Yuko Journal: Lancet oncology Issue: Volume 20:Issue 11(2019) Page Start: 1506 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗